Page 1 of 1
Page 1 of 1
The global smart insulin pens market was valued at $94.76 million in 2020, and is projected to reach $298.87 million by 2030, growing at a CAGR of 12.1% from 2021 to 2030.
Global insulin syringes market was valued at $1,561.20 million in 2020, and is projected to reach $2,401.51 million by 2030, registering a CAGR of 4.4% from 2021 to 2030. Insulin regulates fat ...
The global implantable insulin pump market size was valued at $2,674 million in 2020, and is projected to reach $6,443 million by 2030, registering a CAGR of 9.1% from 2021 to 2030. ...
The global rapid acting insulin market size was valued at $7,100 million in 2019, and is projected to reach $8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027.
The U.S. mhealth device market accounted for $12.11 billion in 2019, and is expected to reach $53.25 billion by 2028, registering a CAGR of 19.6% from 2021 to 2028.
The global syringes market was valued at $15,340 million in 2019, and is projected to reach $32,394.74 million by 2027, registering a CAGR of 9.6 % from 2020 to 2027.
The global smart insulin or glucose responsive insulin market size was valued at $2,773.73 million in 2019, and is expected to reach $6,174.30 million by 2027, registering a CAGR of 10.5% from 2020 to 2027.
The global continuous glucose monitoring systems (CGMS) market size was valued at $1,774.2 million in 2019, and is projected to reach $8,844.9 million by 2027, registering a CAGR of 22.0% during the forecast period.
The global digital diabetes management market was valued at $3,375.8 million in 2018 and is projected to reach $17,118.7 million by 2026, registering a CAGR of 22.5% from 2019 to 2026.
The global polycystic ovarian syndrome treatment market size was valued at $2,902 million in 2018, and is projected to reach $4,184 million by 2026, registering a CAGR of 4.7% from 2019 to 2026.
Global Needle-Free Injection Systems Market was valued at $8,166 million in 2016, and is estimated to reach $23,116 million by 2023, growing at a CAGR of 16.0% from 2017 to 2023. Needle-free ...
Insulin a glucose directing hormone, is an essential part of the treatment plan for many patients with advanced type 2 diabetes mellitus (T2DM) and patients with T1DM. Insulin facilitates the diversion of ...
Insulin occurs in nature and is used for lowering glucose hormones by many diabetic people for the regulation of blood sugar. People who suffer from type 1 diabetes are compensated by supplementary ...
Animal insulin is a derivative of pigs and cows. Animal insulin was the primary sort of insulin to be regulated to control diabetes. Until the 1980s, creature insulin was the lone treatment ...
Insulin moves sugar (glucose) from blood to cells for energy or capacity. On the off chance that you take insulin, you may require some at supper time to assist with bringing down ...
Premixed insulin is a blend of two insulin combined as one, one insulin that is short-acting or effective in addition to one insulin that is halfway acting. The primary kind aides the ...
A pharmaceutical ingredient is any mixture of substances or substance that is intended to be used in the production of a medicine or a therapeutic product.
Page 1 of 1
There might be something that we haven’t covered in the scope and if it is as per your specific areas of interest, we can anytime customise and incorporate your requirements in the framework of the study and provide you with a customised report based on your exact needs.
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers